GlassScriptPhysician profile
John D Price
NPI 1205254679
$7,805.18
in general payments reported to CMS, 2019-2025
11 companies · $71.07 in 2025
The $71.07 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $420 · 2021: $7,101 · 2022: $13.41 · 2023: $31.73 · 2024: $68.55 · 2025: $71.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,654.63 | 2020-2022 | |
| Intuitive Surgical, INC. | $618.69 | 2020-2023 | |
| Glaxosmithkline, LLC. | $152.31 | 2020-2025 | Nucala |
| Pulmonx Corporation | $145.75 | 2021-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Genentech USA, INC. | $99.99 | 2019 | |
| United Therapeutics Corporation | $39.77 | 2020 | |
| Inspire Medical Systems, INC. | $28.29 | 2025 | Inspire |
| Baxter Healthcare | $22.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.